{"id":"W4389893007","doi":"10.1016/j.msard.2023.105328","title":"Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Relapsing remitting; Clinical trial; Physical therapy; Oncology; Immunology; Fingolimod","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01950038,0.003187025,0.005664875,0.0009522235,0.001072294,0.001843775,0.001081272,0.002931888,0.01256765],"category_scores_gemma":[0.02013591,0.00111906,0.004923788,0.001205872,0.002026799,0.001964121,0.0007135876,0.003794295,0.001610638],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00142793,"about_ca_system_score_gemma":0.002400603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005750827,"about_ca_topic_score_gemma":0.001007914,"domain_scores_codex":[0.9854614,0.008571452,0.001893242,0.001997442,0.0009074292,0.001169034],"domain_scores_gemma":[0.9910418,0.003563668,0.002991522,0.0007605104,0.0007532128,0.0008891951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.980093,0.001691167,0.002271064,0.001433772,0.003176054,0.00003947689,0.00005466928,0.0004349519,0.0009111351,0.000417346,0.00109239,0.008385038],"study_design_scores_gemma":[0.9266783,0.05058503,0.01029231,0.0002837269,0.00415528,0.00008516003,0.00005177068,0.0006837508,0.0006935328,0.001716615,0.004698486,0.00007606213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6653425,0.05141854,0.01689222,0.002881107,0.002847826,0.2218317,0.02321544,0.0005018375,0.01506885],"genre_scores_gemma":[0.7070189,0.00530751,0.01375736,0.004595829,0.0009762006,0.2558063,0.00735738,0.0001021451,0.005078418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01950038,"threshold_uncertainty_score":0.1031291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1882112032418722,"score_gpt":0.3692451553097669,"score_spread":0.1810339520678947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}